Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

72.14
+1.221.72%
Post-market: 72.140.00000.00%19:30 EDT
Volume:931.19K
Turnover:66.39M
Market Cap:4.05B
PE:6.50
High:72.22
Open:70.69
Low:70.69
Close:70.92
52wk High:74.59
52wk Low:59.47
Shares:56.10M
Float Shares:56.10M
Volume Ratio:0.94
T/O Rate:1.66%
Dividend:0.81
Dividend Rate:1.12%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.45
PE(LYR):23.58

Loading ...

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
Oct 06

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS
·
Oct 06

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live
·
Oct 06

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

TIPRANKS
·
Oct 06

AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study

Reuters
·
Oct 06

Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study

TIPRANKS
·
Oct 06

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Reuters
·
Oct 06

Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl

THOMSON REUTERS
·
Oct 06

Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated

THOMSON REUTERS
·
Oct 06

Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
Oct 06

Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug

TIPRANKS
·
Oct 06

Sector Update: Healthcare Stocks Rise Monday Afternoon

MT Newswires Live
·
Oct 06

Exchange-Traded Funds Rise, US Equities Higher After Midday

MT Newswires Live
·
Oct 06

Lilly Expands Oncology Footprint with FDA Win for Pancreatic Cancer Drug

Dow Jones
·
Oct 05

UnitedHealth Group Faces Texas AG Investigation Over Coverage Practices

MT Newswires Live
·
Oct 05